A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinomal Evaluating the Efficacy and Safety
Study of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma
Sponsor: UroGen Pharma
Enrolling: Male and Female Patients
IRB Number: AAAQ9319
U.S. Govt. ID: NCT02449239
Contact: Ojas Shah, MD: 212-305-0114 / os2302@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effect and safety of MitoGel on patients with Upper TractUrothelial Carcinoma (UTUC). This research study is being done because this is a potentially beneficial new treatment for Low Grade UTUC. Mitomycin C (MMC) is FDA approved for other clinical indications and commercially available for the treatment of bladder cancer. UroGens MitoGel (a combination of Mitomycin C (MMC) and TC-3 gel) has not been approved by the FDA and is not commercially available. The gel is designed to safely maintain the MMC within the body to treat the bladder cancer. About 74 subjects will take part in this study worldwide.
This study is closed
Investigator
Ojas Shah, MD
Do You Qualify?
Do you have non-invasive UTUC? Yes No
Do you have bladder cancer? Yes No
Have you had bladder cancer during the past 5 years? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ojas Shah, MD
os2302@cumc.columbia.edu
212-305-0114
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE